마크롤라이드계 항생제 시장 규모, 점유율, 성장 분석 : 약제별, 투여 경로별, 적응증별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Macrolide Antibiotics Market size was valued at USD 5.93 Billion in 2024 and is poised to grow from USD 6.07 Billion in 2025 to USD 7.28 Billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global market for macrolide antibiotics is being driven by an increase in infectious disease prevalence, particularly respiratory and sexually transmitted infections. Characterized by their macrocyclic lactone structure and ability to inhibit bacterial protein synthesis, macrolides, while typically bacteriostatic, can exhibit bactericidal effects at higher doses. They are widely utilized to treat conditions such as pneumonia, bronchitis, chlamydia, and gonorrhea. The rising incidence of community-acquired pneumonia, notably influenced by demographics, enhances the demand for these antibiotics. Additionally, the growing accessibility of generic macrolide options contributes to market expansion, as stakeholders focus on developing cost-effective alternatives to established brand-name products. This trend underscores the strategic potential for increased market share in the macrolide antibiotics sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macrolide Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macrolide Antibiotics Market Segments Analysis

Global Macrolide Antibiotics Market is segmented by Drugs, Administration, Indication, End User and region. Based on Drugs, the market is segmented into Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin. Based on Administration, the market is segmented into Oral and Parenteral. Based on Indication, the market is segmented into Infection due to mycoplasma pneumonia, Legionella sp,or Bordetella pertussis, Symptomatic cat-scratch disease, Bacillary angiomatosis, Peliosis hepatis in patients with AIDS, Cebebral taxoplasmosis, Uncomplicated skin infection and Others. Based on End User, the market is segmented into Hospitals, Dermatology clinics, Pharmaceutical companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macrolide Antibiotics Market

The global macrolide antibiotics market is poised for significant growth, particularly in emerging economies such as China, India, and Brazil. These regions, characterized by large populations and escalating healthcare expenses, demonstrate a heightened demand for effective antibiotics. Moreover, the increasing prevalence of bacterial infections in these markets creates ample opportunities for manufacturers to expand their presence and tap into the growing need for efficient treatment solutions. As healthcare infrastructure continues to develop, the macrolide antibiotics sector stands to benefit from the rising awareness of health issues and the urgency to address infectious diseases effectively.

Restraints in the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market faces significant challenges due to the increasing prevalence of microorganisms that have developed resistance to antibiotics. This resistance, especially to macrolides, stems largely from the overuse and inappropriate use of these medications. As antibiotic resistance rises, the long-term viability of macrolide antibiotics as effective treatments for bacterial infections may diminish. Addressing this concerning trend necessitates the development of innovative drugs and alternative therapeutic strategies to effectively combat antibiotic-resistant bacteria and ensure continued efficacy in treating infections.

Market Trends of the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market is currently experiencing significant growth, driven by the urgent need to combat rising bacterial resistance and enhance treatment efficacy. This trend is characterized by increased research and development efforts aimed at creating novel macrolide derivatives and innovative formulations that improve pharmacokinetics and broaden their therapeutic range. Pharmaceutical companies are prioritizing the development of advanced macrolide antibiotics to address evolving microbial threats and optimize existing treatments for diverse illnesses. This proactive approach reflects a commitment to ensuring safety and effectiveness in combating bacterial infections, ultimately shaping the future landscape of the macrolide antibiotic market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Macrolide Antibiotics Market Size by Drugs & CAGR (2026-2033)

• Market Overview
• Azithromycin
• Clarithromycin
• Erythromycin
• Fidaxomicin
• Telithromycin

Global Macrolide Antibiotics Market Size by Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral

Global Macrolide Antibiotics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Infection due to mycoplasma pneumonia
• Legionella sp,or Bordetella pertussis
• Symptomatic cat-scratch disease
• Bacillary angiomatosis
• Peliosis hepatis in patients with AIDS
• Cebebral taxoplasmosis
• Uncomplicated skin infection
• Others

Global Macrolide Antibiotics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Dermatology clinics
• Pharmaceutical companies
• Others

Global Macrolide Antibiotics Market Size & CAGR (2026-2033)

• North America (Drugs, Administration, Indication, End User)
  • US
  • Canada
• Europe (Drugs, Administration, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drugs, Administration, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drugs, Administration, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drugs, Administration, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Guobang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations